Eagle Capital Management (New York)’s Neurotrope, Inc. Common NTRP Stock Holding History

Eagle Capital Management (New York)’s Portfolio NTRP Stock Details NTRP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-59,745	Closed	-$479K	–	56
2019 Q2	$479K	Hold	59,745	–	–	﹤0.01%	54
2019 Q1	$326K	Hold	59,745	–	–	﹤0.01%	57
2018 Q4	$213K	Hold	59,745	–	–	﹤0.01%	58
2018 Q3	$526K	Hold	59,745	–	–	﹤0.01%	53
2018 Q2	$578K	Hold	59,745	–	–	﹤0.01%	51
2018 Q1	$486K	Hold	59,745	–	–	﹤0.01%	53
2017 Q4	$421K	Hold	59,745	–	–	﹤0.01%	56
2017 Q3	$308K	Hold	59,745	–	–	﹤0.01%	53
2017 Q2	$560K	Buy	+59,745	New	+$638K	﹤0.01%	49

Other funds holding NTRP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

OCMI

Oaktop Capital Management II Chatham, New Jersey $1.34B AUM 114.5% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eagle Capital Management (New York)'s NTRP Position: Q3 2019 in Review

Eagle Capital Management (New York) sold out of Neurotrope, Inc. Common (NTRP) in Q3 2019, closing a stake of 59,745 shares — an estimated $479K sold.

Eagle Capital Management (New York) first reported a position in NTRP in Q2 2017 and held it in 9 quarters. The position peaked at $578K in Q2 2018. 29 funds tracked by Wall St. Rank hold NTRP as of Q3 2019.

Eagle Capital Management (New York) reported no remaining Neurotrope, Inc. Common position as of Q3 2019 after selling out during the quarter.
Eagle Capital Management (New York) sold 59,745 Neurotrope, Inc. Common shares in Q3 2019, an estimated $479K.
Eagle Capital Management (New York) first reported a position in Neurotrope, Inc. Common in Q2 2017 and held it in 9 quarters.
Eagle Capital Management (New York)'s Neurotrope, Inc. Common position peaked at $578K in Q2 2018.
29 funds tracked by Wall St. Rank held Neurotrope, Inc. Common as of Q3 2019.

Based on Eagle Capital Management (New York)'s 13F filing for Q3 2019, filed 14 Nov 2019.